<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412059</url>
  </required_header>
  <id_info>
    <org_study_id>LichterM</org_study_id>
    <nct_id>NCT02412059</nct_id>
  </id_info>
  <brief_title>Topical Use of Corticosteroid to Prevent Epiretinal Membrane Following Retinal Tear</brief_title>
  <official_title>Topical Use of Corticosteroid to Prevent Epiretinal Membrane Formation in Eyes With Retinal Tear Undergoing Laser Retinopexy: a Pilot Prospective Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective randomized controlled double blind pilot clinical study, we aim to assess
      whether administration of a topical corticosteroid would attenuate epiretinal membrane
      formation following development of retinal tears treated with laser retionpexy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epiretinal membrane (ERM) is a frequent, sight-threatening eye condition occurring in 1.02% -
      28.9% of eyes in persons aged 40 years or older. [1] While often idiopathic in nature, ERM
      formation has been associated with retinal tears, possibly due to a breakdown of the
      blood-retinal barrier [1-3]. Pathological analysis of ERM content shows inflammatory
      mediators such as cytokines, growth factors and interleukins, which can promote fibroblast
      remodelling that leads to a contractile scar formation on the retinal surface. [1, 4-8] For
      this reason, ERM formation has been suggested to be an aberrant tissue repair or
      wound-healing process driven by inflammatory reactions. Since corticosteroids inhibit the
      inflammatory cascade and fibroblast transdifferentiation, administration of a corticosteroid
      following retinal tears should theoretically reduce the risk of ERM formation. [9-10] In this
      study, we aim to assess whether administration of a topical corticosteroid would attenuate
      ERM formation following laser retinopexy of retinal tears.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of epiretinal membrane</measure>
    <time_frame>6-months following administration of corticosteroid</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Epiretinal Membrane</condition>
  <arm_group>
    <arm_group_label>Prednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pred Forte (prednisolone acetate ophthalmic suspension, USP) 1% sterile</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in control group will not be given a corticosteroid as per usual standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone acetate</intervention_name>
    <arm_group_label>Prednisolone</arm_group_label>
    <other_name>Pred Forte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between ages 18 to 80 (inclusive)

          -  English-speaking

          -  Undergoing non-pneumatic laser retinopexy procedure for horseshoe retinal tear
             (without retinal detachment)

        Exclusion Criteria:

          -  Patient refusal or delay of retinopexy procedure for more than 48 hours after
             diagnosis

          -  Patients who are pseudophakic or aphakic

          -  Medical conditions contraindicated with prednisolone: viral diseases of the cornea and
             conjunctiva including herpes simplex, vaccinia, varicella; fundal diseases of ocular
             structures; mycobacterial infections; hypercortisolism.

          -  Previous history of epiretinal membrane, retinal surgery (cryo or laser)

          -  Patients with hypersensitivity or contraindication for corticosteroids (viral diseases
             of the cornea and conjunctiva including herpes simplex, vaccinia, varicella; fungal
             diseases of ocular structures; mycobacterial infections; hypercortisolism).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myrna Lichter, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto Department of Ophthalmology</affiliation>
  </overall_official>
  <reference>
    <citation>Bu SC, Kuijer R, Li XR, Hooymans JM, Los LI. Idiopathic epiretinal membrane. Retina. 2014 Dec;34(12):2317-35. doi: 10.1097/IAE.0000000000000349. Review.</citation>
    <PMID>25360790</PMID>
  </reference>
  <reference>
    <citation>Saran BR, Brucker AJ. Macular epiretinal membrane formation and treated retinal breaks. Am J Ophthalmol. 1995 Oct;120(4):480-5. Review. Erratum in: Am J Ophthalmol 1996 Mar;121(3):334.</citation>
    <PMID>7573306</PMID>
  </reference>
  <reference>
    <citation>Snead DR, James S, Snead MP. Pathological changes in the vitreoretinal junction 1: epiretinal membrane formation. Eye (Lond). 2008 Oct;22(10):1310-7. doi: 10.1038/eye.2008.36. Epub 2008 Mar 14.</citation>
    <PMID>18344963</PMID>
  </reference>
  <reference>
    <citation>Joshi M, Agrawal S, Christoforidis JB. Inflammatory mechanisms of idiopathic epiretinal membrane formation. Mediators Inflamm. 2013;2013:192582. doi: 10.1155/2013/192582. Epub 2013 Nov 11. Review.</citation>
    <PMID>24324293</PMID>
  </reference>
  <reference>
    <citation>Gilbert C, Hiscott P, Unger W, Grierson I, McLeod D. Inflammation and the formation of epiretinal membranes. Eye (Lond). 1988;2 Suppl:S140-56. Review.</citation>
    <PMID>3076143</PMID>
  </reference>
  <reference>
    <citation>Hiscott PS, Unger WG, Grierson I, McLeod D. The role of inflammation in the development of epiretinal membranes. Curr Eye Res. 1988 Sep;7(9):877-92.</citation>
    <PMID>3180837</PMID>
  </reference>
  <reference>
    <citation>Grinnell F. Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol. 1994 Feb;124(4):401-4. Review.</citation>
    <PMID>8106541</PMID>
  </reference>
  <reference>
    <citation>Banerjee PJ, Woodcock MG, Bunce C, Scott R, Charteris DG. A pilot study of intraocular use of intensive anti-inflammatory; triamcinolone acetonide to prevent proliferative vitreoretinopathy in eyes undergoing vitreoretinal surgery for open globe trauma; the Adjuncts in Ocular Trauma (AOT) Trial: study protocol for a randomised controlled trial. Trials. 2013 Feb 13;14:42. doi: 10.1186/1745-6215-14-42.</citation>
    <PMID>23406256</PMID>
  </reference>
  <reference>
    <citation>Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol. 1980 Jan;89(1):131-6.</citation>
    <PMID>6153251</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2015</study_first_submitted>
  <study_first_submitted_qc>April 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2015</study_first_posted>
  <last_update_submitted>January 28, 2016</last_update_submitted>
  <last_update_submitted_qc>January 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epiretinal Membrane</mesh_term>
    <mesh_term>Retinal Perforations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

